The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Myoepithelial carcinoma: Defining natural history and therapeutic outcomes in a rare malignancy.
 
Madison Ginn
No Relationships to Disclose
 
Davis Ingram
No Relationships to Disclose
 
Khalida Wani
No Relationships to Disclose
 
Diana Shamsutdinova
No Relationships to Disclose
 
Emma Garcia Lopez
No Relationships to Disclose
 
Wei-Lien Wang
No Relationships to Disclose
 
Alexander Lazar
Leadership - Archer; Iterion Therapeutics; Modella; Nucleai
Stock and Other Ownership Interests - Archer; Beta Cat Pharmaceuticals; PAIGE.AI
Honoraria - Bristol-Myers Squibb; Genentech/Roche; Janssen Oncology; Novartis
Consulting or Advisory Role - Abbvie; Bayer; BMS; Deciphera; Moderna/Merck Collaboration; Novartis
Research Funding - AstraZeneca; MedImmune; Novartis; Roche
Patents, Royalties, Other Intellectual Property - Elsevier
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Novartis
 
J. Livingston
Consulting or Advisory Role - Ipsen
Research Funding - Exelixis (Inst); Genentech/Roche (Inst)
Travel, Accommodations, Expenses - Ipsen
Other Relationship - Guidepoint Global
 
Ryan Denu
No Relationships to Disclose
 
Renata Ferrarotto
Consulting or Advisory Role - Answers in CME; Bicara Therapeutics; Coherus Biosciences; Eisai; Johnson & Johnson/Janssen; Labcorp Drug Development; Pyxis; Raptor Pharmaceuticals; Regeneron; Rgenta
Research Funding - Avacta Life Sciences (Inst); Bicara Therapeutics (Inst); Gilead Sciences (Inst); ISA Pharmaceuticals (Inst); Merck Serono (Inst); Pfizer/EMD Serono (Inst); Remix Therapeutics (Inst); Rgenta (Inst); Seagen (Inst); Viracta Therapeutics (Inst)
Patents, Royalties, Other Intellectual Property - Royalties on UpToDate chapter on olfactory neuroblastoma, ~ 300 dollars per year
Travel, Accommodations, Expenses - Bicara Therapeutics
 
Ehab Hanna
No Relationships to Disclose
 
Kelly Hunt
Honoraria - AstraZeneca; Merck
Consulting or Advisory Role - Armada Health Care; AstraZeneca; Daiichi Sankyo/Astra Zeneca
Research Funding - CairnSurgical (Inst); Lumicell (Inst)
Travel, Accommodations, Expenses - Merck
 
B. Ashleigh Guadagnolo
No Relationships to Disclose
 
Jack Phan
No Relationships to Disclose
 
Shreyaskumar Patel
Consulting or Advisory Role - Daiichi Sankyo; Deciphera; Kura Oncology; Thermosome
Research Funding - Ascendo (Inst); Kura Oncology (Inst)
 
Robert Benjamin
Stock and Other Ownership Interests - Gilead Sciences (I); Johnson & Johnson (I)
 
Joseph Ludwig
Research Funding - Lirium Therapeutics